Evidence sheet · a company

Inovio

Inovio has one drug before the FDA: INO-3107, due 30 October 2026. In politics, it is listed as a member of two groups, no lobbying is filed under its own name and one political committee carries its name.

Its drugs on the board

• 30 Oct 2026INO-3107standing: concern recorded; our call: below average

A model portfolio kept for research. It is not an offer, a solicitation or a recommendation to buy or sell any security, and it is not personal advice. The calls are on how the FDA is likely to decide, read from the FDA's own register. The potential return on the first screen combines them with the major banks' targets and each company's cash; it illustrates the room's inputs and is not a forecast of any share price. No money is invested. Past decision-day moves describe a handful of events and predict nothing.

Political connections

• Lobbying. No lobbying filed under its own name in the record.
• Groups it is listed in. California Life Sciences source; Life Sciences Pennsylvania source.
• Political committees. INOVIO PHARMACEUTICALS, INC. DNA MEDICINES POLITICAL ACTION COMMITTEE source.

Directors and officers, 11

• Simon X. Benito sourcedirector
• Peter Kies sourceexecutive officer
• Roger D. Dansey, M.D. sourcedirector
• Ann C. Miller, M.D. sourcedirector
• Michael Sumner, M.D. sourceexecutive officer
• Jacqueline E. Shea, Ph.D. sourcedirector and executive officer
• David B. Weiner, Ph.D. sourcedirector
• Laurent M. Humeau, Ph.D. sourceexecutive officer
• Jay P. Shepard sourcedirector
• Wendy L. Yarno sourcedirector
• Lota S. Zoth sourcedirector

Largest holders

• Listed as holding 5% or more, per the company's own ownership table. Alyeska Investment Group, L.P. source; FMR LLC source; Janus Henderson Group plc source.
• Five largest on Form 13F. ADAR1 Capital Management, LLC source; Boxer Capital Management, LLC source; FMR LLC source; Jupiter Topco LLC source; VANGUARD CAPITAL MANAGEMENT LLC source.